Diabetes group taps biotech vet to direct funding

Last week the Juvenile Diabetes Research Foundation found their new chief at a stem cell company. Novocell CEO Alan Lewis was tapped to head the group, which funds cutting edge research projects into new therapies to fight Type 1 diabetes. Lewis' 30-year track record in drug discovery includes a stint as vice president of research at Wyeth Laboratories.

Public financing of drug research has been flat for the past five years, leaving non-profit groups like the JDRF to pick up much of the slack. The 600 person non-profit group awarded $156 million to researchers last year and has contributed $1.3 billion to diabetes research since it was founded in 1970. And one of its grants was directed to Novocell in 2007, part of a broad program aimed at encouraging small biotech companies.

"Dr. Lewis has a track record of bringing therapies to the clinic, of managing complex scientific organizations, and of spurring innovation across a range of diseases including diabetes and other chronic diseases," said Leo Mullin, chairman of the JDRF International board of directors.

- here's the release
- read the report from the San Diego Union-Tribune

Related Articles:
Novocell reports breakthrough in diabetes cure
Diabetes breakthrough relies on single injection
Fat cell research points to new approach on obesity
Developers, geneticists brainstorm diabetes therapies
FDA mulls tougher standards on diabetes research